Literature DB >> 33387128

Organizational Capacity and Readiness to Provide Medication for Individuals with Co-Occurring Alcohol Use Disorders in Public Mental Health Settings.

Katherine E Watkins1, Sarah B Hunter2, Catherine C Cohen2, Isabel Leamon2, Brian Hurley3, Michael McCreary4, Allison J Ober2.   

Abstract

Alcohol use disorders (AUD) in individuals with mental illness are largely untreated. The purpose of this study was to identify gaps in organizational capacity and readiness to provide medications for AUD in outpatient public mental health clinics. We selected a purposive sample of eight publicly funded outpatient mental health clinics operated by the Los Angeles County Department of Mental Health; clinics were chosen to maximize heterogeneity. Guided by theories of organizational capacity and readiness and research on the adoption of pharmacotherapy for AUD in primary and specialty care treatment settings, we conducted semi-structured interviews and focus groups with administrators, providers and staff, and a qualitative analysis of the results. Respondents described significant organizational capacity and behavioral readiness constraints to providing medication treatment for AUD. Both groups articulated a perception that mental health clinics were not designed to provide co-occurring AUD treatment because of large caseloads, staffing configurations, and time constraints that did not support the delivery of appropriate treatment, and a lack of protocols and workflow procedures. We documented organizational capacity and readiness constraints which impede the delivery of medication treatment for AUD in a large mental helth system. While some constraints have straightforward solutions, others require structural changes to the way care is delivered, and state-level funding and policy changes.

Entities:  

Keywords:  Alcohol use disorders; Co-occurring disorders; Integrated treatment; Mental illness; Pharmacotherapy

Mesh:

Year:  2021        PMID: 33387128      PMCID: PMC8628547          DOI: 10.1007/s10488-020-01103-5

Source DB:  PubMed          Journal:  Adm Policy Ment Health        ISSN: 0894-587X


  45 in total

1.  Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006.

Authors:  Young-Hee Yoon; Chiung M Chen; Hsiao-Ye Yi; Howard B Moss
Journal:  Compr Psychiatry       Date:  2010-12-13       Impact factor: 3.735

2.  Substance abuse with mental disorders: specialized public systems and integrated care.

Authors:  M Audrey Burnam; Katherine E Watkins
Journal:  Health Aff (Millwood)       Date:  2006 May-Jun       Impact factor: 6.301

Review 3.  Are you ready? How health professionals can comprehensively conceptualize readiness for change.

Authors:  Daniel T Holt; Christian D Helfrich; Carmen G Hall; Bryan J Weiner
Journal:  J Gen Intern Med       Date:  2010-01       Impact factor: 5.128

4.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.

Authors:  Paul M Roman; Amanda J Abraham; Hannah K Knudsen
Journal:  Addict Behav       Date:  2011-01-27       Impact factor: 3.913

5.  Comorbid depression and substance abuse among safety-net clients in Los Angeles: a community participatory study.

Authors:  Evelyn T Chang; Kenneth B Wells; James Gilmore; Lingqi Tang; Anna U Morgan; Starr Sanders; Bowen Chung
Journal:  Psychiatr Serv       Date:  2014-12-01       Impact factor: 3.084

Review 6.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Authors:  Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

Review 7.  Building Capacity for Evidence-Based Public Health: Reconciling the Pulls of Practice and the Push of Research.

Authors:  Ross C Brownson; Jonathan E Fielding; Lawrence W Green
Journal:  Annu Rev Public Health       Date:  2017-11-20       Impact factor: 21.981

8.  Counselor training and attitudes toward pharmacotherapies for opioid use disorder.

Authors:  Lydia Aletraris; Mary Bond Edmond; Maria Paino; Dail Fields; Paul M Roman
Journal:  Subst Abus       Date:  2015-07-13       Impact factor: 3.716

9.  Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes.

Authors:  William B Hawthorne; David P Folsom; David H Sommerfeld; Nicole M Lanouette; Marshall Lewis; Gregory A Aarons; Richard M Conklin; Ellen Solorzano; Laurie A Lindamer; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2012-01       Impact factor: 3.084

10.  Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.

Authors:  Allison J Ober; Katherine E Watkins; Sarah B Hunter; Brett Ewing; Karen Lamp; Mimi Lind; Kirsten Becker; Keith Heinzerling; Karen C Osilla; Allison L Diamant; Claude M Setodji
Journal:  BMC Fam Pract       Date:  2017-12-21       Impact factor: 2.497

View more
  3 in total

1.  Improving Medication Access within Integrated Treatment for Individuals with Co-Occurring Disorders in Substance Use Treatment Agencies.

Authors:  James H Ford; Arveen Kaur; Deepika Rao; Aaron Gilson; Daniel M Bolt; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern
Journal:  Implement Res Pract       Date:  2021-09-17

2.  Conceptualizing the Socio-Built Environment: An Expanded Theoretical Framework to Promote a Better Understanding of Risk for Nonmedical Opioid Overdose Outcomes in Urban and Non-Urban Settings.

Authors:  Barbara Tempalski; Leslie D Williams; Marynia Kolak; Danielle C Ompad; Julia Koschinsky; Sara L McLafferty
Journal:  J Urban Health       Date:  2022-06-07       Impact factor: 5.801

3.  Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders.

Authors:  James H Ford; Deepika Rao; Aaron Gilson; Arveen Kaur; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern
Journal:  J Dual Diagn       Date:  2022-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.